ArticleFrontiers in microbiology2024
Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Multimodal graph learning for chagas disease classification.Medical & biological engineering & computing · 2026Article
- Comparison of Cobas Plasma Separation Cards and Whatman filter paper cards versus conventional serum samples for anti-Trypansoma cruzi antibody detection.PLoS neglected tropical diseases · 2026Article
- Evaluation of Chagas TESA VirClia assay for chronicJournal of clinical microbiology · 2026Article
- Chagas disease in Florida: An emerging one health challenge in the United States.One health (Amsterdam, Netherlands) · 2026Article
- Beyond Pilot Data: Reframing Tc-24 ELISA in the Diagnostic Ecology of Canine Chagas Disease.Veterinary medicine and science · 2026Article
- Diagnostic methods for protozoan diseases: a review focused on leishmaniasis, Chagas disease and malaria.Frontiers in microbiology · 2026Review
- Chagas Disease: An Opportunistic Infection in AIDS.Current infectious disease reports · 2026Article
- Evaluation of a Novel Tc-24 Recombinant Antigen ELISA for Serologic Detection of Trypanosoma cruzi Infection in Dogs: A Pilot Study.Veterinary medicine and science · 2025Article
- Rapid High-Sensitivity Detection of Antibodies to Trypanosoma cruzi With a Recombinant Tc24 Antigen-Based Magneto-Immunoassay: A Pilot Study.The Journal of infectious diseases · 2025Article
- Chagas Disease in a Non-Endemic Setting: Clinical Profile, Treatment Outcomes, and Predictors of Cure in a 15-Year Cohort Study.Tropical medicine and infectious disease · 2025Article
- Diagnosing Chagas in Pregnancy and Childhood: What's Old and New.Clinics in laboratory medicine · 2025Review
- Article
- Evaluation of strategies for the diagnosis of Chagas disease in an endemic area: SaMi-Trop study.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chagas disease (CD), caused by Methods: A literature search in PubMed was conducted on studies related to Results: Out of 85 studies included in the final review, 115 different tests were identified. These tests comprised 89 serological test types, 21 molecular test types, and 5 other test methods. Predominant serological tests included ELISA (38 studies, 44.70%), Rapid tests (19 studies, 22.35%), and chemiluminescence (10 studies, 11.76%). Among molecular tests, Polymerase Chain Reaction (PCR) assays were notable. Twenty-eight tests were approved globally for IVD or donor testing, all being serological methods. Molecular assays lacked approval for IVD in the United States, with only European and Colombian regulatory acceptance. Discussion and conclusion: Serological tests, specifically ELISAs, remain the most used and commercially available diagnostic methods. This makes sense considering that most Chagas disease diagnoses occur in the chronic phase and that the WHO gold standard relies on 2 serological tests to establish the diagnosis of chronic Chagas. ELISAs are feasible and relatively low-cost, with good performance with sensitivities ranging between 77.4% and 100%, and with specificities ranging between 84.2% and 100%. Molecular methods allow the detection of specific variants but rely on the parasite's presence, which limits their utility to parasitemia levels. Depending on the PCR method and the phase of the disease, the sensitivity ranged from 58.88 to 100% while the mean specificity ranged from 68.8% to 100%. Despite their performance, molecular testing remains mostly unavailable for IVD use. Only 3 molecular tests are approved for IVD, which are available only in Europe. Six commercial serological assays approved by the FDA are available for blood and organ donor screening. Currently, there are no guidelines for testing CD oral outbreaks. Although more evidence is needed on how testing methods should be used in special clinical scenarios, a comprehensive approach of clinical assessment and diagnostics tests, including not IVD methods, is required for an accurate CD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.